Abzena

? This Thanksgiving, we reflect on the incredible dedication of our team and the trust of our partners, who make it possible to advance life-changing therapeutics. At Abzena, every milestone is a step toward improving patient outcomes and shaping the future of healthcare. We are thankful for the opportunity to contribute to the success of programs that impact lives worldwide. ? #Thanksgiving #Gratitude #Innovation #Abzena

Register today for our upcoming Q&A panel-style webinar hosted by Biospring Partners on Dec 17th at 11:30am EST/ 4:30pm GMT, entitled: "Cell Line Development Strategies that Reduce Timelines & Costs."? ? Hear from Abzena’s CSO, Campbell Bunce PhD MBA, and VP of Cell Line Development, Simon Keen, along with ProteoNic’s, VP of Business Development, Jonathan Frampton, and VP of Biospring Partners, Socrates Zacharias, as they share expert insights and answer live audience questions on the challenges and considerations that drug developers face when trying to develop a high-producing cell line.? ? Covering topics ranging from integrated development strategies to vector technologies, they will discuss how enhanced CLD technologies can increase your biologic’s chances of success in the clinic and beyond. ? Click here to register: https://lnkd.in/ecWYemrk ? #CellLineDevelopment #Biologics #DrugDevelopment #CDMO #Webinar #CRO

Chemistry plays a major role in developing a manufacturable Antibody-drug conjugate (ADC). From the design and optimization of synthetic routes to developing novel linker-payloads, these challenging steps require extensive expertise in order to deliver a scalable and high-quality ADC. ? Our latest info sheet, "Complex Chemistry for Antibody-Drug Conjugates and Beyond," explores how Abzena’s advanced chemistry solutions drive the rapid development of highly potent compounds and bioconjugates. Our expertise across small molecules, peptides, and oligos coupled with our integrated approach, enables us to provide innovative strategies that confidently advance ADC programs from discovery through clinical and commercial stages. ? Read the full info sheet to discover how our specialized chemistry capabilities can streamline your ADC's development journey: https://lnkd.in/eNR9hn72 ? #ADCDevelopment #ComplexChemistry #DrugDevelopment #Bioconjugation #CDMO #CRO

To mitigate some of the biggest risks in drug development, it’s essential to gather as much information about a candidate early on in development to make better, more informed decisions further down the line. This is where "developability" comes in, to understand whether the drug can be made and if it will work. ? At the recent Biologics US conference, our Sr. Director of Bioassays, Dr Erika Kovacs, presented a scientific poster entitled: "Rapid Developability Assessments to Assist Lead Candidate Selection." ?The poster highlights our robust developability platform, which integrates in silico approaches with characterization and stability studies to determine the selection of the best candidate to progress. ? Using a panel of 7 mAb sequences, the poster details the different computational tools employed to identify sequence liabilities and immunogenicity risks, while advanced biophysical techniques evaluated manufacturability and stability. ? Click here to access the poster: https://lnkd.in/euVZDnwG ? #Developability #LeadSelection #DrugDevelopment?#CRO #CDMO

Bioconjugates are complex molecules that can be challenging to analyze and characterize. Robust bioassays and phase-appropriate analytical methods are necessary to produce high-quality, well-characterized material and the data needed to support successful regulatory submissions. ? At Abzena, we address these challenges by leveraging our extensive analytical expertise and state-of-the-art instrumentation to develop and qualify phase-appropriate assays that accurately assess the safety, potency, purity, identity and extended characterization of your biopharmaceutical. Our customized approach delivers rapid, high-quality data to support informed decision-making across the entire drug development lifecycle. ? From compendial assessments on pH and appearance to GMP cell-based potency testing that ensures critical cytotoxicity data for regulatory submissions, our advanced capabilities provide our customers with comprehensive and reliable solutions for their programs. ? Discover how Abzena’s analytical expertise can streamline your bioconjugate program: https://lnkd.in/g7BtucAa ? #ADCCDMO #Bioassays #Analytical #DrugDevelopment #CDMO #CRO

In our continued celebration of World Quality Month, Dr Louise Duffy, our Chief Technical and Quality Officer, shares her thoughts on elevating quality to the next level across everything we do at Abzena. Louise emphasizes to our team that every action we take has a quality impact. Working on highly complex molecules at the cutting-edge of design and development presents unique technical challenges. Hear how Louise reminds us of our critical role in delivering these next-gen therapeutics to improve patient lives. #WorldQualityMonth #QualityExcellence #DrugDevelopment #QualityAndCompliance #CDMO #CRO

At BEBPA, we presented a poster entitled, "Streamlining the Development of Relative Potency Assays for ADCs."?The poster delved into the essential role that relative potency assays play in maintaining the efficacy and potency of biologics throughout their lifecycle. ? This work focused on designing bespoke assays tailored to the complex mechanisms of action (MoAs) of antibody-drug conjugates (ADCs). These assays encompass critical steps in ADC functionality, including target binding, internalization, intracellular payload release, and tumor cell elimination. By comprehensively addressing these processes, we can develop robust, regulatory-compliant assays that support ADC development from early-stage research through clinical trials. ? Access the full poster here: https://lnkd.in/eqbh8WiZ ? #ADCCRO #ADCCDMO #Bioassay #PotencyAssays #DrugDevelopment

Last chance to register! Join our #webinar with Promega UK today at 3pm GMT / 10am EST entitled: "Always Look on the Bright Side of (Cell) Death: Cytotoxicity Assays for Antibody Drug Conjugate Development." Hear from Abzena’s experts, Grant Harradence & Robert J Francis PhD FRMS, as they discuss how advanced bioassays are driving innovation in antibody-drug conjugate (ADC) development. This webinar will explore how Abzena applies developability principles throughout the drug development process. Using two approved ADCs as examples, our speakers will demonstrate the robustness of bioassays in 3D cell culture models and highlight biological methods that support lead candidate selection for further discovery. ? Register now to discover how Abzena & Promega's expertise can help advance your ADC: https://bit.ly/4hRF7mP #ADCCRO #drugdevelopment #bioconjugates #CDMO https://lnkd.in/gGrgftX8??

NEWS: We are thrilled to announce the expansion of our early and late-phase analytical capabilities to now include #GMP cell-based potency assays at our Cambridge, UK and San Diego, CA development and manufacturing facilities. GMP cell-based potency assays play an essential role in quantitatively measuring the biological activity of a biopharmaceutical, and the cytotoxicity of the payload of an Antibody-drug conjugate (ADC), for both GMP product release and stability testing.? Our CSO, Campbell Bunce PhD MBA shares, "Our established expertise and reputation have allowed us to extend our early-phase capabilities to include GMP cell-based potency services at our global sites, addressing a critical need for our customers. This significant milestone further demonstrates our commitment to providing comprehensive, end-to-end support for our customer’s next-generation programs that drive successful outcomes from discovery to the clinic and onwards towards commercial.” Read the full press release here: https://lnkd.in/gM6mEzgd #drugdevelopment #CDMO #CRO #biopharmaceuticals #analytical #bioassays

Philadelphia has a rich history of drug development and manufacturing innovations which support its reputation as a life sciences hub. In a recent BioBuzz feature, Abzena was highlighted as one of the city's prominent CDMOs, for our ongoing contributions to the region, including a $5 million investment in our Bristol, PA facility to enhance bioconjugation and ADC manufacturing capabilities. ? The investment included expanded QC and analytical laboratory space, new chromatography and purification equipment, and facility upgrades. These additions further enhanced the site's existing bioconjugation capabilities and increased its capacity to support the delivery of fully integrated biopharmaceutical drug programs. ? Learn more about how Abzena is driving bioconjugate innovation in the Philadelphia area: https://lnkd.in/eZXADjiF ? #CDMO #ADCCDMO #ADCDevelopment #Bioconjugation #DrugSubstance